After the close today, Genentech marched into the earnings confessional to reveal that third-quarter earnings came in at $685 million, or 64 cents per share, compared with year-ago earnings of $568 million, or 53 cents per share. Excluding items, earnings rolled in at 73 cents per share, beating the Street estimate by a penny. Sales for the quarter jumped to $2.91 billion, falling just shy of the Street estimate of $2.93 billion.

Shares of DNA are down slightly in after-hours action following a gain of 0.32% in regular trading. Today marked the stock's first close above its 10-day moving average since September 27. However, the equity's upside was capped by its 20-day trendline.

In trading today, the stock's October 80 call was the site of heaviest volume, as more than 10,000 contracts crossed the tape on open interest of 23,000 contracts. On the put side, the October 75 put was the most active with more than 5,000 contracts changing hands on open interest of 5,100 contracts.